Swiss biotech ADC Therapeutics announced the closure of its U.K. research site, discontinuation of certain solid tumor programs, and a workforce reduction of 30%. These steps follow the termination of its only clinical-stage candidate, reflecting a strategic retrenchment with significant impacts on its development pipeline and personnel.